""People living with obesity need treatment options that meet them where they are - and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment.""
""With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials - addressing both the clinical realities of obesity and the practical challenges patients face every day.""
""Eli Lilly is aiming to ensure the new pill is affordable for patients. Those with commercial insurance may pay just $25 per month with the Foundayo savings card, while self-pay users can expect to pay $149 monthly for the lowest dose.""
Eli Lilly's new GLP-1 pill, Foundayo, has received FDA approval for adults with obesity or weight-related health issues. Clinical trials indicated an average weight loss of 27.3 pounds with Foundayo compared to 2.2 pounds with a placebo. The medication will be available through LillyDirect and retail pharmacies, with shipping starting on April 6. Foundayo offers a needle-free alternative for patients, with affordability options including a $25 monthly cost for insured patients and $149 for self-pay users. It is the first oral GLP-1 option since Wegovy's approval in December 2025.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]